+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Latin America and Middle & Africa (LAMEA) Indapamide Market 2020-2026

  • PDF Icon


  • August 2020
  • Region: Africa, Latin America
  • Orion Market Research Private Limited
  • ID: 5148129
Latin America and Middle & Africa (LAMEA) Indapamide Market Size, Share & Trends Analysis Report by product (1.25 mg and 2.5 mg), By Application (High Blood Pressure, Heart Failure, and Others), and Forecast 2020-2026.

The LAMEA prazosin market is estimated to grow significantly during the forecast period. The factors contributing to the growth of the indapamide market include rising cases of diabetes and hypertension among the population. According to the International Diabetes Federation (IDF), Brazil and Mexico are the two countries with a higher number of diabetes cases registered in the region. In Mexico, an estimated 12 million cases were registered in 2017. Additionally, the diabetes cases are expected to rise by 35% to an estimated 16 million cases by 2045 in Mexico. Moreover, according to the World Health Organization (WHO), diabetes is the second-most common cause of mortality in Mexico. Hence, indapamide drugs have great potential to offer for diabetes in the market of the RoW region. Some of the major factors that are contributing to the increasing cases of diabetes include rapid urbanization and changing lifestyles across the region.

The LAMEA indapamide market is segmented on the basis of product and application. Based on the product, the market is bifurcated into 1.25 mg indapamide and 2.5 mg indapamide. Among these, the market for 1.25 mg medicine held a significant share owing to the extensive application of the drug in treating high blood pressure or hypertension. Based on the application, the market is segmented into high blood pressure, heart failure, and others. The high blood pressure segment is projected to have a significant share in the market. Growing incidence of hypertension is contributing to market growth as indapamide drugs are significantly used to treat hypertension while reducing the risk of developing serious heart conditions.

Some of the global companies operating in the LAMEA indapamide market include ANI Pharmaceuticals, Inc., Apotex Inc., Sanofi S.A., Teva Pharmaceuticals Industries Ltd., Mylan N.V., and others. The market players are considerably contributing to market growth by adopting various strategies to stay competitive in the market.

Research Methodology:

The market study of the LAMEA prazosin market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for indapamide market players, pharmaceutical companies, drug manufacturers, government organizations, regulatory bodies, and other market participants for the overall market and competitive analysis. The report provides an in-depth analysis on market size, products offered by the companies, and future market opportunities. The report will serve as a source for 360-degree analysis of the market delivering insights into the market for making better business decisions.

Market Segmentation:

1. LAMEA Indapamide Market Research and Analysis by Product
2. LAMEA Indapamide Market Research and Analysis by Application

The Report Covers:
  • Comprehensive research methodology of the LAMEA Indapamide market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the LAMEA Indapamide market.
  • Insights about market determinants which are stimulating the LAMEA Indapamide market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Key Strategy Analysis
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. LAMEA Indapamide Market by Product
5.1.1. 1.25 MG
5.1.2. 2.5 MG
5.2. LAMEA Indapamide Market by Application
5.2.1. High Blood Pressure
5.2.2. Heart Failure
5.2.3. Others
6. Regional Analysis
6.1. Latin America
6.2. Middle East
6.3. Africa
7. Company Profiles
7.1. ANI Pharmaceuticals, Inc.
7.2. Glenmark Pharmaceuticals Ltd.
7.3. Grupo Azevedos
7.4. Krka Group
7.5. Mylan N.V.
7.6. Merck KGaA
7.7. Sanofi S.A.
7.8. Sandoz International GmbH
7.9. Servier Group
7.10. Teva Pharmaceuticals Industries Ltd.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • ANI Pharmaceuticals, Inc.
  • Glenmark Pharmaceuticals Ltd.
  • Grupo Azevedos
  • Krka Group
  • Mylan N.V.
  • Merck KGaA
  • Sanofi S.A.
  • Sandoz International GmbH
  • Servier Group
  • Teva Pharmaceuticals Industries Ltd.